Trial met primary endpoint, showing Ronapreve significantly reduced viral load in seronegative patients hospitalised with COVID-19 who did not require high-flow oxygen or mechanical ventilation at baselineClinical
Covid-19: More virulent variant of Delta fuels cocktail-resistance fear
BySyed AkbarSyed Akbar / Updated: Jun 14, 2021, 09:21 IST
HYDERABAD: The highly infectious
Covid-19 that first surfaced in
India is feared to have mutated into a more virulent version called AY.1 or Delta+ –– one that is possibly capable of resisting even the monoclonal antibodies cocktail currently being prescribed as a cure for the virus.
According to
Public Health England, an executive agency of the UK government’s health and social care department, 63 genomes of Delta (B.1.617.2) with the new K417N mutation had been identified so far on the global science initiative GISAID. In its latest report on Covid-19 variants, updated till last Friday, India had reported six cases of Delta+ as of June 7.
Covid Delta variant found in India may have mutated into a more dangerous drug-resistant Delta+
SECTIONS
Share
Synopsis
According to Public Health England, 63 genomes of Delta (B.1.617.2) with the new K417N mutation had been identified so far.
Reuters
Delta+ –– one that is possibly capable of resisting even the monoclonal antibodies cocktail currently being prescribed as a cure for the virus.
The highly infectious
Delta variant of Covid-19 that first surfaced in India is feared to have mutated into a more virulent version called AY.1 or Delta+ –– one that is possibly capable of resisting even the monoclonal antibodies cocktail currently being prescribed as a cure for the virus.
Antibody cocktail for Covid emerges as ray of hope, but cost makes it prohibitive for most
Akanksha Chawala, a critical care pulmonologist at Apollo hospital in Delhi, said she had used the therapy in just two patients but the results had been extraordinary.
Share Via Email
| A+A A-
An artist paints No mask No Entry graffiti at Chennai Central Railway station. (File Photo | Martin Louis, EPS)
Express News Service
NEW DELHI: A month after an antibody cocktail was approved for treating mild to moderate Covid-19 in high-risk patients in India, some leading private hospitals in the country have said that they have achieved remarkable results with its usage so far.